Allergic Asthma Therapeutics Market, by Drug Type (Corticosteroids, Bronchodilators, Leukotriene modifiers, Immunotherapy, Biologics, and Others), by Route of Administration (Oral, Inhaled, and Others), and by Region (North America, Latin America, Europe,

Allergic Asthma Therapeutics Market, by Drug Type (Corticosteroids, Bronchodilators, Leukotriene modifiers, Immunotherapy, Biologics, and Others), by Route of Administration (Oral, Inhaled, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Asthma is a long-term inflammatory lung disease which is caused by inflammation and narrowing in the air passage resulting from environmental and genetic influences. Allergic asthma is one of the most common types of asthma. Allergic asthma is triggered by inhaling allergens such as mold, pollen, pet dander, and dust mite allergen resulting in symptoms of allergic asthma which include chest tightness, rapid breathing or shortness of breath, wheezing, and coughing.
Market Dynamics
The rising incidence of respiratory diseases and the growing demand for cost-effective treatments are expected to propel the allergic asthma therapeutics market growth in future. Additionally, an increase in pollution levels and an upsurge in cases of chronic obstructive pulmonary diseases (COPD) are other factors boosting the market growth. According to the World Health Organization (WHO), more than 200 million people suffer from COPD and around 235 million have asthma all across the globe.
Allergic asthma therapeutics are cost-effective and gaining popularity among patients and healthcare professionals due to launches of novel drugs by key players. This is estimated to drive the market growth during the forecast period.
Moreover, governments are taking initiatives to provide better care and treatment for patients, and are focusing on increasing awareness about allergic asthma which is contributing to the allergic asthma therapeutics market growth. However, the increasing use of generic drugs and upsurge in patent expiry of drugs are predicted to restrict the market growth in the forecast period.
Key features of the study:
This report provides in-depth analysis of the global allergic asthma therapeutics market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains an attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global allergic asthma therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
Key players covered as a part of this study are Aslan Pharmaceuticals Pte. Ltd., Baxalta Incorporated, Axikin Pharmaceuticals, Chiesi Farmaceutici SpA, CSL Limited, Circassia Pharmaceuticals Plc, Fountain Biopharma Inc., Hydra Biosciences, GlaxoSmithKline Plc, Infinity Pharmaceuticals, Mabtech Limited, Kineta, Marinomed Biotechnologie Gmb, NeoPharm Co., Mycenax Biotech Inc., Panacea Biotec Limited, and Oxagen Limited.
Insights from this report would allow marketers and management authorities of companies to make an informed decision with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global allergic asthma therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for allergic asthma therapeutics market, research and consulting firms, new entrants, and financial analysts.
Detailed Segmentation:
Global Allergic Asthma Therapeutics Market, By Drug Type:
Corticosteroids
Bronchodilators
Leukotriene modifiers
Immunotherapy
Biologics
Others
Global Allergic Asthma Therapeutics Market, By Route of Administration:
Oral
Inhaled
Others
Global Allergic Asthma Therapeutics Market, By Region:
North America
By Country:
U.S.
Canada
By Drug Type:
Corticosteroids
Bronchodilators
Leukotriene modifiers
Immunotherapy
Biologics
Others
By Route of Administration:
Oral
Inhaled
Others
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drug Type:
Corticosteroids
Bronchodilators
Leukotriene modifiers
Immunotherapy
Biologics
Others
By Route of Administration:
Oral
Inhaled
Others
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drug Type:
Corticosteroids
Bronchodilators
Leukotriene modifiers
Immunotherapy
Biologics
Others
By Route of Administration:
Oral
Inhaled
Others
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drug Type:
Corticosteroids
Bronchodilators
Leukotriene modifiers
Immunotherapy
Biologics
Others By Route of Administration:
Oral
Inhaled
Others
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Drug Type:
Corticosteroids
Bronchodilators
Leukotriene modifiers
Immunotherapy
Biologics
Others
By Route of Administration:
Oral
Inhaled
Others
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Drug Type:
Corticosteroids
Bronchodilators
Leukotriene modifiers
Immunotherapy
Biologics
Others By Route of Administration:
Oral
Inhaled
Others
Company Profiles
Aslan Pharmaceuticals, Pte. Ltd.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Baxalta Incorporated
Axikin Pharmaceuticals
Chiesi Farmaceutici SpA
CSL Limited
Circassia Pharmaceuticals Plc
Fountain Biopharma Inc.
Hydra Biosciences
GlaxoSmithKline Plc
Infinity Pharmaceuticals
Mabtech Limited
Kineta
Marinomed Biotechnologie Gmb
NeoPharm Co.
Mycenax Biotech Inc.
Panacea Biotec Limited
Oxagen Limited
“*” marked represents similar segmentation in other categories in the respective section. Show more